Clinical Trials

MERCK -MK8228-040-0 A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post-transplant in cytomegalovirus (CMV) seropositive recipients (R+) of an allogenic hematopoietic stem cell transplant (HSCT


Study ID
MERCK - MK8228-040-0 Dr. Donato

NCT Number
(Click on the NCT number for more information about the trial)

Research Study Number
2018-1109

Principle Investigator
Dr. Michele Donato

Phase
III

Sponsor
Merk


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now